ResMed (RMD) 10-Q 1 May 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2020	Apr. 27, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-15317
Entity Registrant Name	ResMed Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-0152841
Entity Address, Address Line One	9001 Spectrum Center Blvd.
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92123
Entity Address, Country	US
City Area Code	858
Local Phone Number	836-5000
Title of 12(b) Security	Common Stock, par value $0.004 per share
Trading Symbol	RMD
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		144,668,429
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--06-30
Entity Central Index Key	0000943819

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 352,861	$ 147,128
Accounts receivable, net of allowance for doubtful accounts of $28,833 and $25,171 at March 31, 2020 and June 30, 2019, respectively	554,859	528,484
Inventories (note 3)	358,772	349,641
Prepaid expenses and other current assets	203,266	120,113
Total current assets	1,469,758	1,145,366
Non-current assets:
Property, plant and equipment, net (note 3)	397,209	387,460
Operating lease right-of-use assets (note 9)	126,277
Goodwill (note 4)	1,884,458	1,856,449
Other intangible assets, net (note 3)	464,963	521,950
Deferred income taxes	27,321	45,478
Prepaid taxes and other non-current assets	140,557	150,979
Total non-current assets	3,040,785	2,962,316
Total assets	4,510,543	4,107,682
Current liabilities:
Accounts payable	116,148	115,725
Accrued expenses	235,201	266,359
Operating lease liabilities, current (note 9)	22,795
Deferred revenue	97,110	88,667
Income taxes payable (note 6)	68,278	73,248
Short-term debt, net (note 8)	11,987	11,992
Total current liabilities	551,519	555,991
Non-current liabilities:
Deferred revenue	84,615	81,143
Deferred income taxes	25,441	11,380
Operating lease liabilities, non-current (note 9)	107,251
Other long-term liabilities	7,527	2,058
Long-term debt, net (note 8)	1,364,849	1,258,861
Long-term income taxes payable (note 6)	112,910	126,056
Total non-current liabilities	1,702,593	1,479,498
Total liabilities	2,254,112	2,035,489
Commitments and contingencies (note 12)
Stockholders’ equity: (note 10)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 186,498,704 issued and 144,662,470 outstanding at March 31, 2020 and 185,491,064 issued and 143,654,830 outstanding at June 30, 2019	579	575
Additional paid-in capital	1,533,905	1,511,473
Retained earnings	2,711,639	2,436,410
Treasury stock, at cost, 41,836,234 shares at March 31, 2020 and June 30, 2019	(1,623,256)	(1,623,256)
Accumulated other comprehensive loss	(366,436)	(253,009)
Total stockholders' equity	2,256,431	2,072,193
Total liabilities and stockholders' equity	$ 4,510,543	$ 4,107,682

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, net allowance for doubtful accounts	$ 28,833	$ 25,171
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	186,498,704	185,491,064
Common stock, shares outstanding	144,662,470	143,654,830
Treasury stock, shares held	41,836,234	41,836,234

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statements Of Income [Abstract]
Net revenue	$ 769,455	$ 662,228	$ 2,186,669	$ 1,901,608
Cost of sales (exclusive of amortization shown separately below)	307,657	270,318	880,633	782,874
Amortization of acquired intangible assets	12,136	10,940	37,623	27,095
Total cost of sales	319,793	281,258	918,256	809,969
Gross profit	449,662	380,970	1,268,413	1,091,639
Operating expenses:
Selling, general and administrative	172,441	164,529	511,304	473,410
Research and development	51,449	47,610	149,425	129,513
Amortization of acquired intangible assets	8,272	11,854	21,872	24,406
Litigation settlement expenses			(600)
Acquisition related expenses				6,123
Total operating expenses	232,162	223,993	682,001	633,452
Income from operations	217,500	156,977	586,412	458,187
Other income (loss), net:
Interest income	116	415	766	2,014
Interest expense	(9,968)	(12,413)	(31,180)	(23,608)
Loss attributable to equity method investments (note 5)	(5,295)	(5,996)	(19,082)	(9,371)
Other, net	(10,698)	(1,054)	(15,922)	(4,140)
Total other income (loss), net	(25,845)	(19,048)	(65,418)	(35,105)
Income before income taxes	191,655	137,929	520,994	423,082
Income taxes	28,518	32,513	77,155	87,291
Net income	$ 163,137	$ 105,416	$ 443,839	$ 335,791
Basic earnings per share (note 11)	$ 1.13	$ 0.74	$ 3.08	$ 2.35
Diluted earnings per share (note 11)	1.12	0.73	3.05	2.33
Dividend declared per share	$ 0.39	$ 0.37	$ 1.17	$ 1.11
Basic shares outstanding (000's)	144,638	143,316	144,112	142,907
Diluted shares outstanding (000's)	145,680	144,333	145,490	144,344

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 163,137	$ 105,416	$ 443,839	$ 335,791
Other comprehensive income (loss):
Foreign currency translation (loss) gain adjustments	(120,318)	(2,501)	(113,427)	(28,490)
Comprehensive income	$ 42,819	$ 102,915	$ 330,412	$ 307,301

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Beginning balance at Jun. 30, 2018	$ 571	$ 1,450,821	$ (1,600,412)	$ 2,432,328	$ (224,328)	$ 2,058,980
Beginning balance, shares at Jun. 30, 2018	184,316,000		(41,636,000)
Common stock issued on exercise of options		513				513
Common stock issued on exercise of options, shares	12,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax		(141)				(141)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	2,000
Treasury stock purchases	$ (1)		$ (22,844)			(22,845)
Treasury stock purchases, shares			(200,000)
Stock-based compensation costs		12,476				12,476
Other comprehensive income					(12,872)	(12,872)
Net income				105,738		105,738
Dividends declared				(52,794)		(52,794)
Ending balance at Sep. 30, 2018	$ 570	1,463,669	$ (1,623,256)	2,296,473	(237,200)	1,900,256
Ending balance, shares at Sep. 30, 2018	184,330,000		(41,836,000)
Beginning balance at Jun. 30, 2018	$ 571	1,450,821	$ (1,600,412)	2,432,328	(224,328)	$ 2,058,980
Beginning balance, shares at Jun. 30, 2018	184,316,000		(41,636,000)
Common stock issued on employee stock purchase plan, shares						129,000
Treasury stock purchases						$ (22,800)
Treasury stock purchases, shares						(200,000)
Net income						$ 335,791
Ending balance at Mar. 31, 2019	$ 573	1,476,099	$ (1,623,256)	2,420,731	(252,818)	2,021,329
Ending balance, shares at Mar. 31, 2019	185,182,000		(41,836,000)
Cumulative effect of change in accounting standards				(188,799)		(188,799)
Beginning balance at Sep. 30, 2018	$ 570	1,463,669	$ (1,623,256)	2,296,473	(237,200)	1,900,256
Beginning balance, shares at Sep. 30, 2018	184,330,000		(41,836,000)
Common stock issued on exercise of options		1,263				1,263
Common stock issued on exercise of options, shares	36,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	$ 2	(27,343)				(27,341)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	623,000
Common stock issued on employee stock purchase plan	$ 1	10,575				10,576
Common stock issued on employee stock purchase plan, shares	129,000
Stock-based compensation costs		12,541				12,541
Other comprehensive income					(13,117)	(13,117)
Net income				124,639		124,639
Dividends declared				(52,773)		(52,773)
Ending balance at Dec. 31, 2018	$ 573	1,460,705	$ (1,623,256)	2,368,339	(250,317)	1,956,044
Ending balance, shares at Dec. 31, 2018	185,118,000		(41,836,000)
Common stock issued on exercise of options		2,896				2,896
Common stock issued on exercise of options, shares	55,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax		(330)				(330)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	9,000
Stock-based compensation costs		12,828				12,828
Other comprehensive income					(2,501)	(2,501)
Net income				105,416		105,416
Dividends declared				(53,024)		(53,024)
Ending balance at Mar. 31, 2019	$ 573	1,476,099	$ (1,623,256)	2,420,731	(252,818)	2,021,329
Ending balance, shares at Mar. 31, 2019	185,182,000		(41,836,000)
Beginning balance at Jun. 30, 2019	$ 575	1,511,473	$ (1,623,256)	2,436,410	(253,009)	2,072,193
Beginning balance, shares at Jun. 30, 2019	185,491,000		41,836,000
Common stock issued on exercise of options		5,609				5,609
Common stock issued on exercise of options, shares	110,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax		(327)				(327)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	4,000
Stock-based compensation costs		13,256				13,256
Other comprehensive income					(37,576)	(37,576)
Net income				120,148		120,148
Dividends declared				(56,052)		(56,052)
Ending balance at Sep. 30, 2019	$ 575	1,530,011	$ (1,623,256)	2,500,506	(290,585)	2,117,251
Ending balance, shares at Sep. 30, 2019	185,605,000		41,836,000
Beginning balance at Jun. 30, 2019	$ 575	1,511,473	$ (1,623,256)	2,436,410	(253,009)	$ 2,072,193
Beginning balance, shares at Jun. 30, 2019	185,491,000		41,836,000
Common stock issued on exercise of options, shares						260,666
Common stock issued on employee stock purchase plan, shares						137,000
Treasury stock purchases						$ (1,600,000)
Treasury stock purchases, shares						(41,800,000)
Net income						$ 443,839
Ending balance at Mar. 31, 2020	$ 579	1,533,905	$ (1,623,256)	2,711,639	(366,436)	2,256,431
Ending balance, shares at Mar. 31, 2020	186,499,000		(41,836,000)
Beginning balance at Sep. 30, 2019	$ 575	1,530,011	$ (1,623,256)	2,500,506	(290,585)	2,117,251
Beginning balance, shares at Sep. 30, 2019	185,605,000		41,836,000
Common stock issued on exercise of options		6,498				6,498
Common stock issued on exercise of options, shares	117,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	$ 3	(40,764)				(40,761)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	576,000
Common stock issued on employee stock purchase plan		12,190				12,190
Common stock issued on employee stock purchase plan, shares	137,000
Stock-based compensation costs		14,057				14,057
Other comprehensive income					44,467	44,467
Net income				160,554		160,554
Dividends declared				(56,150)		(56,150)
Ending balance at Dec. 31, 2019	$ 578	1,521,992	$ (1,623,256)	2,604,910	(246,118)	2,258,106
Ending balance, shares at Dec. 31, 2019	186,435,000		(41,836,000)
Common stock issued on exercise of options	$ 1	1,815				1,816
Common stock issued on exercise of options, shares	34,000
Common stock issued on vesting of restricted stock units, net of shares withheld for tax		(4,014)				(4,014)
Common stock issued on vesting of restricted stock units, net of shares withheld for tax, shares	30,000
Stock-based compensation costs		14,112				14,112
Other comprehensive income					(120,318)	(120,318)
Net income				163,137		163,137
Dividends declared				(56,408)		(56,408)
Ending balance at Mar. 31, 2020	$ 579	$ 1,533,905	$ (1,623,256)	$ 2,711,639	$ (366,436)	$ 2,256,431
Ending balance, shares at Mar. 31, 2020	186,499,000		(41,836,000)

Condensed Consolidated Statem_4

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income	$ 443,839	$ 335,791
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	116,341	108,203
Amortization of right-of-use-assets	19,524
Stock-based compensation costs	41,421	37,856
Loss attributable to equity method investments (note 5)	19,082	9,371
Impairment of equity investments (note 5)	14,519	8,801
Gain on previously held equity interest (note 13)		(1,909)
Changes in fair value of business combination contingent consideration	(7)	(272)
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(34,140)	(1,482)
Inventories	(22,564)	(55,002)
Prepaid expenses, net deferred income taxes and other current assets	(68,724)	(17,453)
Accounts payable, accrued expenses and other	(57,301)	(106,671)
Net cash provided by operating activities	471,990	317,233
Cash flows from investing activities:
Purchases of property, plant and equipment	(77,360)	(46,507)
Patent registration costs	(7,391)	(6,556)
Business acquisitions, net of cash acquired (note 13)	(27,910)	(951,565)
Purchases of investments (note 5)	(31,616)	(31,092)
Payments on maturity of foreign currency contracts	(32,177)	3,902
Net cash used in investing activities	(176,454)	(1,031,818)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	26,112	15,346
Taxes paid related to net share settlement of equity awards	(45,106)	(27,880)
Purchases of treasury stock		(22,844)
Payments of business combination contingent consideration	(302)	(648)
Proceeds from borrowings, net of borrowing costs	990,000	1,414,230
Repayment of borrowings	(883,012)	(541,394)
Dividend paid	(168,610)	(158,592)
Net cash provided by (used in) financing activities	(80,918)	678,218
Effect of exchange rate changes on cash	(8,885)	(5,821)
Net increaase (decrease) in cash and cash equivalents	205,733	(42,188)
Cash and cash equivalents at beginning of period	147,128	188,701
Cash and cash equivalents at end of period	352,861	146,513
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	150,801	211,816
Interest paid	31,180	23,608
Fair value of assets acquired, excluding cash	14,922	400,804
Liabilities assumed	(4,294)	(320,923)
Goodwill on acquisition	20,550	879,419
Deferred payments	232	(7,568)
Fair value of contingent consideration	(3,500)	(167)
Cash paid for acquisitions	$ 27,910	$ 951,565

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2020. The condensed consolidated financial statements for the three and nine months ended March 31, 2020 and March 31, 2019 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2019. Revenue Recognition We adopted Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” on July 1, 2018. We account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software-as-a-service to out-of-hospital health providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting. Disaggregation of revenue The following table summarizes our net revenue disaggregated by segment, product and region (in thousands): Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 U.S., Canada and Latin America Devices $ 196,497 $ 181,269 $ 586,907 $ 540,190 Masks and other 197,052 168,726 584,901 494,792 Total Sleep and Respiratory Care $ 393,549 $ 349,995 $ 1,171,808 $ 1,034,982 Software as a Service 89,560 79,942 263,156 190,614 Total $ 483,109 $ 429,937 $ 1,434,964 $ 1,225,596 Combined Europe, Asia and other markets Devices $ 195,038 $ 155,178 $ 509,274 $ 463,053 Masks and other 91,308 77,113 242,431 212,959 Total Sleep and Respiratory Care $ 286,346 $ 232,291 $ 751,705 $ 676,012 Global revenue Devices $ 391,535 $ 336,447 $ 1,096,181 $ 1,003,243 Masks and other 288,360 245,839 827,332 707,751 Total Sleep and Respiratory Care $ 679,895 $ 582,286 $ 1,923,513 $ 1,710,994 Software as a Service 89,560 79,942 263,156 190,614 Total $ 769,455 $ 662,228 $ 2,186,669 $ 1,901,608 Performance obligations and contract balances Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products are provided at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years . The following table summarizes our contract balances (in thousands): March 31, 2020 June 30, 2019 Balance sheet caption Contract assets Accounts receivable, net $ 554,859 $ 528,484 Accounts receivable, net Unbilled revenue, current 8,545 9,834 Prepaid expenses and other current assets Unbilled revenue, non-current 5,920 4,592 Prepaid taxes and other non-current assets Contract liabilities Deferred revenue, current ( 97,110 ) ( 88,667 ) Deferred revenue (current liabilities) Deferred revenue, non-current ( 84,615 ) ( 81,143 ) Deferred revenue (non-current liabilities) Transaction price determination Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g., rebates, discounts, free goods) and returns offered to customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs. Many of our Sleep and Respiratory Care contracts have a single performance obligation which is the shipment of our therapy-based equipment. However, when the Sleep and Respiratory Care or SaaS contract has multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to the performance obligation. Provision for Warranty We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision. New Accounting Pronouncements (a) Recently issued accounting standards not yet adopted ASU No. 2016-13 “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” (Topic 326), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The guidance is effective for us beginning in the first quarter of the fiscal year ending June 30, 2021 and will be adopted using a modified retrospective approach. We currently do not expect the adoption to have a material impact on our consolidated financial statements. ASU No. 2017-04 “Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment” In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment” (Topic 350). ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. This guidance is effective for us beginning in the fourth quarter of fiscal year June 30, 2020 and early adoption is permitted. We currently perform a Step 0, or qualitative, impairment assessment for our Reporting Units, which we expect to continue and, therefore, anticipate that the adoption of ASU 2017-04 will not have a material impact on our consolidated financial statements. ASU No. 2018-15 “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (Subtopic 350-40), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for us beginning in the first quarter of the fiscal year ending June 30, 2021 and will be applied prospectively. Under the new ASU, capitalized implementation costs will be presented as other non-current assets on our consolidated balance sheets and within operating cash flows on our consolidated statements of cash flows. The adoption of this ASU is not expected to have a material effect on our consolidated financial statements. ASU No. 2020-04 “Reference Rate Reform: Facilitation of the Effects of Reference Rate Reform on Financial Reporting” In March 2020, the FASB issued ASU No. 2020-04, “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (Topic 848), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance is effective for us as of March 12, 2020 through December 31, 2022. We are currently evaluating the impact that this guidance, if elected, will have on our consolidated financial statements. (b) Recently adopted accounting pronouncements ASU No. 2016-02, “Leases” In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset (“ROU”) and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases are classified as either operating or finance under the new guidance. Operating leases result in straight-line expense in the income statement, similar to prior operating lease treatment, and finance leases result in more expense being recognized in the earlier years of the lease term, similar to prior capital lease treatment. For lessors, the update more closely aligns lease accounting to comparable guidance in the new revenue standards described. Effective, July 1, 2019, we adopted the new standard on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In addition, we elected the package of practical expedients permitted under the transition guidance to not reassess (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. In preparation for and upon adoption of this guidance, we have designed and operated internal controls over its implementation, which includes a system solution for lease administration, accounting and disclosures of financial information surrounding our leasing arrangements. The adoption of the guidance on July 1, 2019 resulted in the recognition of ROU assets of $ 77.6 million and lease liabilities of $ 81.3 million, which all related to operating leases. The ROU assets were lower than the lease liabilities due to the derecognition of deferred rent balances of $ 3.7 million. We did not recognize any adjustment to the comparative period presented in the financial statements in accordance with our adoption method. The guidance did not have a material impact on our condensed consolidated statements of income. In our Form 10-K for the year ended June 30, 2019, we estimated that the adoption of the guidance would result in the recognition of additional ROU assets and lease liabilities for operating leases of approximately $ 60.0 million to $ 70.0 million as of July 1, 2019. This range excluded the impact of our evaluation of lease terms, several contracts that may contain an embedded lease and the final assessment of the lease discount rates. During the quarter ended September 30, 2019, we finalized all remaining implementation work and the increase from our estimate of $ 60.0 million to $ 70.0 million to the opening balance of $ 77.6 million was primarily driven by our determination that we were reasonably certain to exercise extension options at some of our major sites, partially offset by our final discount rates generally being lower than the preliminary rate of 3.5 % that was used when calculating our estimated balance upon adoption. See note 9 - Leases for further disclosures related to our leases under the new guidance. (c) Adjustment to prior periods Within our condensed consolidated statements of income for the three and nine months ended March 31, 2020 and 2019, cost of sales has been adjusted to include amortization of acquired intangible assets directly applicable to revenue. As a result, gross profit now includes amortization of acquired intangible assets relating to cost of sales and operating expenses have been reduced by this amount. There was no impact on income from operations, income before taxes or net income, as a result of this reclassification. The adjustments to the previously reported amounts are not material. The table below presents a reconciliation of amortization of acquired intangible assets by income statement caption summing to total amortization of acquired intangible assets as previously reported (in thousands): Three Months Ended Nine Months Ended March 31, 2019 Amortization of intangible assets related to cost of sales $ 10,940 $ 27,095 Amortization of intangible assets related to operating expenses 11,854 24,406 Total $ 22,794 $ 51,501 The table below presents a reconciliation of gross profit as previously reported adjusted for the amortization of acquired intangible assets now included in cost of sales (in thousands): Three Months Ended Nine Months Ended March 31, 2019 Gross profit as previously reported $ 391,910 $ 1,118,734 Amortization of intangible assets related to cost of sales ( 10,940 ) ( 27,095 ) Gross profit $ 380,970 $ 1,091,639

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2020
Segment Information [Abstract]
Segment Information	( 2) Segment Information We have quantitatively and qualitatively determined that we operate in two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in note 1 of our consolidated financial statements included in our Form 10-K for the year ended June 30, 2019. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed. Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, acquisition related expenses, interest income, interest expense and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information. The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands): Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 Revenue by segment Total Sleep and Respiratory Care $ 679,895 $ 582,286 $ 1,923,513 $ 1,710,994 Software as a Service 89,560 82,196 265,258 194,897 Deferred revenue fair value adjustment - ( 2,254 ) ( 2,102 ) ( 4,283 ) Total Software as a Service 89,560 79,942 263,156 190,614 Total $ 769,455 $ 662,228 $ 2,186,669 $ 1,901,608 Net operating profit by segment Sleep and Respiratory Care $ 250,209 $ 190,203 $ 678,468 $ 562,490 Software as a Service 18,738 20,457 63,874 52,737 Total $ 268,947 $ 210,660 $ 742,342 $ 615,227 Reconciling items Corporate costs $ 31,039 $ 28,635 $ 94,933 $ 95,133 Amortization of acquired intangible assets 20,408 22,794 59,495 51,501 Litigation settlement expenses - - ( 600 ) - Acquisition related expenses - - - 6,123 Deferred revenue fair value adjustment - 2,254 2,102 4,283 Interest income ( 116 ) ( 415 ) ( 766 ) ( 2,014 ) Interest expense 9,968 12,413 31,180 23,608 Loss attributable to equity method investments 5,295 5,996 19,082 9,371 Other, net 10,698 1,054 15,922 4,140 Income before income taxes $ 191,655 $ 137,929 $ 520,994 $ 423,082

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Mar. 31, 2020
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Information	(3) Supplemental Balance Sheet Information Components of selected captions in the consolidated condensed balance sheets consisted of the following (in thousands): Inventories March 31, 2020 June 30, 2019 Raw materials $ 98,885 $ 80,861 Work in progress 2,433 2,256 Finished goods 257,454 266,524 Total inventories $ 358,772 $ 349,641 Property, Plant and Equipment March 31, 2020 June 30, 2019 Property, plant and equipment, at cost $ 903,299 $ 898,975 Accumulated depreciation and amortization ( 506,090 ) ( 511,515 ) Property, plant and equipment, net $ 397,209 $ 387,460 Other Intangible Assets March 31, 2020 June 30, 2019 Developed/core product technology $ 380,817 $ 401,842 Accumulated amortization ( 183,720 ) ( 157,651 ) Developed/core product technology, net 197,097 244,191 Customer relationships 277,997 273,114 Accumulated amortization ( 73,681 ) ( 68,630 ) Customer relationships, net 204,316 204,484 Other intangibles 163,761 176,351 Accumulated amortization ( 100,211 ) ( 103,076 ) Other intangibles, net 63,550 73,275 Total other intangibles, net $ 464,963 $ 521,950 Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two years to fifteen years . There are no expected residual values related to these intangible assets.

Goodwill

Goodwill	9 Months Ended
	Mar. 31, 2020
Goodwill [Abstract]
Goodwill	(4) Goodwill A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands): Nine Months Ended March 31, 2020 Sleep and Respiratory Care SaaS Total Balance at the beginning of the period $ 616,965 $ 1,239,484 $ 1,856,449 Business acquisitions 266 20,284 20,550 Adjustment to fair values of preliminary purchase price allocations 526 16,282 16,808 Foreign currency translation adjustments ( 9,349 ) - ( 9,349 ) Balance at the end of the period $ 608,408 $ 1,276,050 $ 1,884,458

Investments

Investments	9 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Investments	(5) Investments We have a number of equity investments in privately held companies that are unconsolidated entities and are recorded in the non-current balance of other assets on the consolidated condensed balance sheets. The following table shows a reconciliation of the changes in all of our investments (in thousands): Nine Months Ended March 31, 2020 2019 Equity method investments Balance at the beginning of the period $ 21,667 $ - Investments 17,500 25,000 Loss attributable to equity method investments ( 19,082 ) ( 9,371 ) Carrying value of equity method investments 20,085 15,629 Non-marketable securities Balance at the beginning of the period $ 30,436 $ 41,226 Investments 14,116 6,092 Impairment of investments ( 14,519 ) ( 8,801 ) Acquisition of controlling interest in previously held investment (note 21) - ( 5,000 ) Carrying value of non-marketable securities 30,033 33,517 Total investments in unconsolidated entities $ 50,118 $ 49,146 Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee’s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments. Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values, and are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We estimate the fair value of our equity investments using Level 3 inputs to assess whether impairment losses shall be recorded.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	(6) Income Taxes In accordance with ASC 740 Income Taxes , each interim reporting period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results . In connection with the audit by the Australian Taxation Office (“ATO”) for the tax years 2009 to 2013 , we received Notices of Amended Assessments in March 2018. Based on these assessments, the ATO asserted that we owe $ 151.7 million in additional income tax and $ 38.4 million in accrued interest, of which $ 75.9 million was paid in April 2018 under a payment arrangement with the ATO. In June 2018, we received a notice from the ATO claiming penalties of 50 % of the additional income tax that was assessed or $ 75.9 million. At March 31, 2020, we recorded a receivable in prepaid taxes and other non-current assets for the amount paid as we ultimately expect this will be refunded by the ATO. The ATO is currently auditing tax years 2014 to 2018 . We do not agree with the ATO’s assessments and continue to believe we are more likely than not to be successful in defending our position.

Product Warranties

Product Warranties	9 Months Ended
	Mar. 31, 2020
Product Warranties [Abstract]
Product Warranties	(7) Product Warranties Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands): Nine Months Ended March 31, 2020 2019 Balance at the beginning of the period $ 19,625 $ 19,227 Warranty accruals for the period 10,879 11,601 Warranty costs incurred for the period ( 9,620 ) ( 10,790 ) Foreign currency translation adjustments ( 1,650 ) ( 405 ) Balance at the end of the period $ 19,234 $ 19,633

Debt

Debt	9 Months Ended
	Mar. 31, 2020
Debt [Abstract]
Debt	(8) Debt Debt consisted of the following (in thousands): March 31, 2020 June 30, 2019 Short-term debt $ 12,000 $ 12,012 Deferred borrowing costs ( 13 ) ( 20 ) Short-term debt, net 11,987 11,992 - Long-term debt $ 1,369,000 $ 1,262,000 Deferred borrowing costs ( 4,151 ) ( 3,139 ) Long-term debt, net $ 1,364,849 $ 1,258,861 Total debt $ 1,376,836 $ 1,270,853 Credit Facility On April 17, 2018, we entered into an amended and restated credit agreement (the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and letter of credit issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $ 800.0 million, with an uncommitted option to increase the revolving credit facility by an additional $ 300.0 million. Additionally, on April 17, 2018, ResMed Limited entered into a Syndicated Facility Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of $ 200.0 million. On November 5, 2018, we entered into a first amendment to the Revolving Credit Agreement to, among other things, increase the size of our senior unsecured revolving credit facility from $ 800.0 million to $ 1.6 billion, with an uncommitted option to increase the revolving credit facility by an additional $ 300.0 million. Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. The Revolving Credit Agreement and Term Credit Agreement each terminate on April 17, 2023 , when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $ 6.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to LIBOR plus 0.75 % to 1.50 % (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0 % to 0.50 % (depending on the then-applicable leverage ratio). At March 31, 2020, the interest rate that was being charged on the outstanding principal amounts was 1.9 %. An applicable commitment fee of 0.100 % to 0.175 % (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. As of March 31, 2020, we had $ 895.0 million available for draw down under the revolving credit facility. We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements’ interest rate is calculated as LIBOR plus the spreads described above, its carrying amount is equivalent to its fair value as at March 31, 2020 and June 30, 2019, which was $ 881.0 million and $ 1,274.0 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value. Senior Notes On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $ 250.0 million principal amount of our 3.24 % senior notes due July 10, 2026 , and $ 250.0 million principal amount of our 3.45 % senior notes due July 10, 2029 (collectively referred to as the “Senior Notes”). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree LLC, Brightree Home Health & Hospice LLC, Brightree Patient Collections LLC, ResMed Operations Inc., HEALTHCAREfirst Holding Company, HCF Holdco Company, HEALTHCAREfirst, Inc., CareFacts Information Systems, LLC and Lewis Computer Services, LLC, MatrixCare Holdings Inc., MatrixCare, Inc., Reciprocal Labs Corporation and ResMed SaaS Inc., under a Subsidiary Guaranty Agreement dated as of July 10, 2019. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement. Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of March 31, 2020, the Senior Notes have a carrying amount of $ 500.0 million, excluding deferred borrowing costs, and an estimated fair value of $ 521.1 million. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value. At March 31, 2020, we were in compliance with our debt covenants and there was $1,381.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.

Leases

Leases	9 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	(9) Leases We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated condensed balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases. Operating lease costs for the three and nine months ended March 31, 2020 were $ 7.2 million and $ 19.6 million, respectively. Short-term and variable lease costs were not material for the three and nine months ended March 31, 2020. Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate): March 31, 2020 Operating lease ROU assets $ 126,277 Operating lease liabilities, current portion 22,795 Operating lease liabilities, non-current portion 107,251 Total operating lease liabilities $ 130,046 Weighted-average remaining lease term (years) 9.0 Weighted-average discount rate 3.07 % Future minimum lease payments under non-cancellable leases as of March 31, 2020 and for the periods ending June 30 of the years indicated below were as follows (in thousands): In $000’s Total 2020 2021 2022 2023 2024 2025 Thereafter Minimum lease payments $ 150,844 $ 7,098 $ 24,744 $ 18,349 $ 14,921 $ 12,178 $ 10,560 $ 62,994 Less: imputed interest ( 20,798 ) Total lease liabilities $ 130,046 As of March 31, 2020, we had additional operating lease commitments of $ 14.0 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2021 with lease terms of 8 years to 11 years. Disclosures related to periods prior to adopting the new lease guidance We lease certain facilities and equipment under operating leases expiring at various dates. Most of the operating leases contain renewal options. Total expense for all operating leases was $ 23.4 million, $ 21.1 million, and $ 20.1 million for the years ended June 30, 2019, 2018, and 2017, respectively. Future minimum lease payments (including interest) under non-cancellable operating leases at June 30, 2019 were as follows (in thousands): Fiscal Years Ending June 30 In $000’s Total 2020 2021 2022 2023 2024 Thereafter Operating leases $ 98,013 $ 23,500 $ 17,161 $ 12,403 $ 9,478 $ 7,916 $ 27,555 The supplemental cash flow information for the three and nine months ended March 31, 2020 was as follows (in thousands): Three Months Ended Nine Months Ended March 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 6,301 $ 17,352 Right of use assets obtained in exchange for new lease liabilities: Operating leases $ 34,876 $ 51,573

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2020
Stockholders' Equity [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity Common Stock. Since the inception of our share repurchase programs and through March 31, 2020, we have repurchased a total of 41.8 million shares for an aggregate of $ 1.6 billion. We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did not repurchase any shares during the nine months ended March 31, 2020. During the nine months ended March 31, 2019, we repurchased 200,000 shares at an aggregate purchase price of $ 22.8 million under our share repurchase program. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. There is no expiration date for this program, and the program may be accelerated, suspended, reinstated, delayed or discontinued at any time at the discretion of our board of directors. At March 31, 2020, 12.9 million additional shares can be repurchased under the approved share repurchase program. Preferred Stock. In April 1997, the board of directors designated 2.0 million shares of our $ 0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at March 31, 2020 and June 30, 2019 . Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the amended and restated ResMed Inc. 2009 Incentive Award Plan (as amended and restated, the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one year to four years . At March 31, 2020, the maximum number of shares of our common stock authorized for issuance under the 2009 Plan was 51.1 million shares. The number of securities remaining available for future issuance under the 2009 Plan at March 31, 2020 was 15.8 million. The following table summarizes option activity during the nine months ended March 31, 2020: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period 1,260,114 $ 72.91 4.4 Granted 162,180 146.34 Exercised ( 260,666 ) 53.41 Forfeited ( 4,342 ) 110.19 Outstanding at end of period 1,157,286 $ 87.45 4.6 Exercise price of granted options $ 146.34 Options exercisable at end of period 724,040 $ 70.70 The following table summarizes the activity of restricted stock units during the nine months ended March 31, 2020: Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period 1,446,170 $ 77.21 1.6 Granted 361,986 140.98 Vested* ( 915,450 ) 61.00 Performance factor adjustment 289,678 - Expired / cancelled ( 31,545 ) 89.37 Forfeited ( 5,023 ) 89.37 Outstanding at end of period 1,145,816 $ 103.46 1.8 * Includes 305,719 shares netted for tax Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. During the nine months ended March 31, 2020 and March 31, 2019, we issued 137,000 and 129,000 shares to our employees associated with the ESPP, respectively. At March 31, 2020, the number of shares remaining available for future issuance under the ESPP is 2.1 million shares.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	(11) Earnings Per Share Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 267,556 and 356,583 for the three months ended March 31, 2020 and March 31, 2019 , respectively, and 128,789 and 161,314 for the nine months ended March 31, 2020 and March 31, 2019, respectively, as the effect would have been anti-dilutive. Basic and diluted earnings per share are calculated as follows (in thousands except per share data): Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 Numerator: Net income $ 163,137 $ 105,416 $ 443,839 $ 335,791 Denominator: Basic weighted-average common shares outstanding 144,638 143,316 144,112 142,907 Effect of dilutive securities: Stock options and restricted stock units 1,042 1,017 1,378 1,437 Diluted weighted average shares 145,680 144,333 145,490 144,344 Basic earnings per share $ 1.13 $ 0.74 $ 3.08 $ 2.35 Diluted earnings per share $ 1.12 $ 0.73 $ 3.05 $ 2.33

Legal Actions And Contingencies

Legal Actions And Contingencies	9 Months Ended
	Mar. 31, 2020
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(12) Legal Actions and Contingencies Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole. Taxation Matters As described in note 6 – Income Taxes, we received Notices of Amended Assessments from the ATO for the tax years 2009 to 2013 . Based on these assessments, the ATO asserted that we owe $ 151.7 million in additional income tax and $ 38.4 million in accrued interest, of which $ 75.9 million was paid in April 2018 under a payment arrangement with the ATO. In June 2018, we received a notice from the ATO claiming penalties of 50 % of the additional income tax that was assessed, or $ 75.9 million. At September 30, 2018, we recorded a receivable in prepaid taxes and other non-current assets for the amount paid as we ultimately expect this will be refunded by the ATO. We do not agree with the ATO’s assessments and we continue to believe we are more likely than not to be successful in defending our position. However, if we are not successful, we will not receive a refund of the amount paid in April 2018 and we would be required to pay the remaining additional income tax, accrued interest and penalties, which would be recorded as income tax expense. The ATO is currently auditing tax years 2014 to 2018 . In connection with recent changes in U.S. tax laws and the analysis of historical tax filings, we identified an administrative oversight in our prior year tax filings relating to a gain on an internal legal entity reorganization. We applied for relief from the U.S. Internal Revenue Service (“IRS”) and amended the related tax returns required to correct the administrative oversight. On March 26, 2020, we received written notice from the IRS stating that our relief requests were granted. As such, no additional tax or penalties are owed and this matter has been closed. Contingent Obligations Under Recourse Provisions We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions’ credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer’s receivable balance is with recourse, either limited or full, whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses. The following table summarizes the amount of receivables sold with recourse (in thousands): Nine Months Ended March 31, 2020 2019 Total receivables sold: Full recourse $ - $ 28,846 Limited recourse 99,785 70,847 Total $ 99,785 $ 99,693 The following table summarizes the maximum exposure on outstanding receivables sold with recourse and provision for doubtful accounts ( in thousands) : March 31, 2020 June 30, 2019 Maximum exposure on outstanding receivables: Full recourse $ 1,870 $ 19,209 Limited recourse 23,436 10,241 Total $ 25,306 $ 29,450 Contingent provision for receivables with recourse $ ( 4,764 ) $ ( 1,752 )

Business Combinations

Business Combinations	9 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combinations	( 13) Business Combinations Nine months ended March 31, 2020 On January 31, 2020, we completed the acquisition of 100 % of the membership interests in SnapWorx, LLC (“SnapWorx”), a software company providing patient contact management and workflow optimization for the sleep apnea resupply market. This acquisition has been accounted for as a business combination using purchase accounting and the results of SnapWorx are included in our consolidated financial statements from the acquisition date. This acquisition is not considered a material business combination and accordingly pro forma information is not provided. The acquisition was funded by drawing on our existing credit facility and through cash on-hand. We have not yet completed the purchase price allocation in relation to the SnapWorx acquisition. We do not believe that the completion of this work will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation during the quarter ending June 30, 2020. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of the acquisition is reflected in the Software as a Service segment and is deductible for tax purposes. It mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. During the nine months ended March 31, 2020 we did no t record any material acquisition-related expenses. Fiscal year ended June 30, 2019 MatrixCare On November 13, 2018, we completed the acquisition of 100 % of the shares in MatrixCare, Inc. and its subsidiaries (“MatrixCare”), a provider of software solutions for skilled nursing, life plan communities, senior living and private duty, for base purchase consideration paid of $ 750.0 million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from November 13, 2018. The acquisition was paid for using borrowings under our revolving credit facility. We completed the purchase price allocation in relation to this acquisition during the quarter ended December 31, 2019. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of the acquisition is reflected in the Software as a Service segment and is not deductible for tax purposes. It mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands): Preliminary as of June 30, 2019 Adjustments Final Intangible assets - useful life Current assets $ 50,325 $ - $ 50,325 Property, plant and equipment 4,401 - 4,401 Trade names 18,000 - 18,000 7 years Developed technology 133,000 - 133,000 7 years Customer relationships 114,000 2,000 116,000 15 years Goodwill 517,995 5,664 523,659 Assets acquired $ 837,721 $ 7,664 $ 845,385 Current liabilities ( 13,751 ) ( 255 ) ( 14,006 ) Deferred revenue ( 18,339 ) ( 166 ) ( 18,505 ) Deferred tax liabilities ( 41,570 ) ( 7,243 ) ( 48,813 ) Debt assumed ( 151,665 ) - ( 151,665 ) Total liabilities assumed $ ( 225,325 ) $ ( 7,664 ) $ ( 232,989 ) Net assets acquired $ 612,396 $ - $ 612,396 A reconciliation of the base consideration to the net consideration is as follows (in thousands): Base consideration $ 750,000 Cash acquired 15,873 Debt assumed ( 151,665 ) Net working capital and other adjustments ( 1,812 ) Net consideration $ 612,396 Other acquisitions During the year ended June 30, 2019, we also completed the following acquisitions:  On July 6, 2018, we completed the acquisition of 100 % of the shares in HEALTHCAREfirst Holding Company (“HEALTHCAREfirst”), a provider of software solutions and services for home health and hospice agencies, for a total purchase consideration of $ 126.3 million.  On October 15, 2018, we completed the acquisition of 100 % of the shares in HB Healthcare, a homecare provider in South Korea.  On December 11, 2018, we completed the acquisition of assets in Interactive Health Network, a provider of integrated clinical and financial management software solution for long-term care companies.  On December 13, 2018, we completed the acquisition of assets in Apacheta, a provider of cloud-based SaaS software that manages the medical equipment delivery process for home medical equipment dealers.  On January 6, 2019, we completed the acquisition of Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease and asthma, for a total purchase consideration of $ 242.9 million, which adjusts for cash acquired and debt assumed at the time of acquisition. We previously held a non-controlling interest in Propeller Health’s outstanding shares. As a result of the acquisition, we recognized a fair value gain of $ 1.9 million in other income during the year ended June 30, 2019 associated with the previous equity investment. These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from the acquisition dates. These acquisitions, individually and collectively, are not considered a material business combination and accordingly pro forma information is not provided. The acquisitions were funded by drawing on our existing credit facility and through cash on-hand. We have completed the purchase price allocation in relation to all of these acquisitions. The cost of the share acquisitions was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is predominantly not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. Goodwill from these acquisitions has been reflected in the Software as a Service segment except for the goodwill resulting from the HB Healthcare and Propeller Health acquisitions, which have been recorded in the Sleep and Respiratory Care segment. The fair values of assets acquired and liabilities assumed of acquisitions during the year ended June 30, 2019, excluding MatrixCare, and the estimated useful lives of intangible assets acquired are as follows (in thousands): Final Intangible assets - useful life Current assets $ 31,648 Property, plant and equipment 2,290 Deferred tax assets 5,211 Trade names 7,828 10 years Non-compete 1,000 3 years Developed technology 48,280 5 to 6 years Customer relationships 53,712 5 to 15 years Goodwill 287,469 Assets acquired $ 437,438 Current liabilities ( 7,648 ) Deferred revenue ( 3,619 ) Deferred tax liabilities ( 2,367 ) Debt assumed ( 35,104 ) Total liabilities assumed $ ( 48,738 ) Net assets acquired $ 388,700 During nine months ended March 31, 2019, we recorded acquisition-related expenses of $ 6.1 million.

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Mar. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition We adopted Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” on July 1, 2018. We account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software-as-a-service to out-of-hospital health providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting. Disaggregation of revenue The following table summarizes our net revenue disaggregated by segment, product and region (in thousands): Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 U.S., Canada and Latin America Devices $ 196,497 $ 181,269 $ 586,907 $ 540,190 Masks and other 197,052 168,726 584,901 494,792 Total Sleep and Respiratory Care $ 393,549 $ 349,995 $ 1,171,808 $ 1,034,982 Software as a Service 89,560 79,942 263,156 190,614 Total $ 483,109 $ 429,937 $ 1,434,964 $ 1,225,596 Combined Europe, Asia and other markets Devices $ 195,038 $ 155,178 $ 509,274 $ 463,053 Masks and other 91,308 77,113 242,431 212,959 Total Sleep and Respiratory Care $ 286,346 $ 232,291 $ 751,705 $ 676,012 Global revenue Devices $ 391,535 $ 336,447 $ 1,096,181 $ 1,003,243 Masks and other 288,360 245,839 827,332 707,751 Total Sleep and Respiratory Care $ 679,895 $ 582,286 $ 1,923,513 $ 1,710,994 Software as a Service 89,560 79,942 263,156 190,614 Total $ 769,455 $ 662,228 $ 2,186,669 $ 1,901,608 Performance obligations and contract balances Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products are provided at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years . The following table summarizes our contract balances (in thousands): March 31, 2020 June 30, 2019 Balance sheet caption Contract assets Accounts receivable, net $ 554,859 $ 528,484 Accounts receivable, net Unbilled revenue, current 8,545 9,834 Prepaid expenses and other current assets Unbilled revenue, non-current 5,920 4,592 Prepaid taxes and other non-current assets Contract liabilities Deferred revenue, current ( 97,110 ) ( 88,667 ) Deferred revenue (current liabilities) Deferred revenue, non-current ( 84,615 ) ( 81,143 ) Deferred revenue (non-current liabilities) Transaction price determination Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g., rebates, discounts, free goods) and returns offered to customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer’s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs. Many of our Sleep and Respiratory Care contracts have a single performance obligation which is the shipment of our therapy-based equipment. However, when the Sleep and Respiratory Care or SaaS contract has multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to the performance obligation.
Provision For Warranty	Provision for Warranty We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.
New Accounting Pronouncements	New Accounting Pronouncements (a) Recently issued accounting standards not yet adopted ASU No. 2016-13 “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” (Topic 326), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The guidance is effective for us beginning in the first quarter of the fiscal year ending June 30, 2021 and will be adopted using a modified retrospective approach. We currently do not expect the adoption to have a material impact on our consolidated financial statements. ASU No. 2017-04 “Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment” In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment” (Topic 350). ASU 2017-04 eliminates step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. This guidance is effective for us beginning in the fourth quarter of fiscal year June 30, 2020 and early adoption is permitted. We currently perform a Step 0, or qualitative, impairment assessment for our Reporting Units, which we expect to continue and, therefore, anticipate that the adoption of ASU 2017-04 will not have a material impact on our consolidated financial statements. ASU No. 2018-15 “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (Subtopic 350-40), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for us beginning in the first quarter of the fiscal year ending June 30, 2021 and will be applied prospectively. Under the new ASU, capitalized implementation costs will be presented as other non-current assets on our consolidated balance sheets and within operating cash flows on our consolidated statements of cash flows. The adoption of this ASU is not expected to have a material effect on our consolidated financial statements. ASU No. 2020-04 “Reference Rate Reform: Facilitation of the Effects of Reference Rate Reform on Financial Reporting” In March 2020, the FASB issued ASU No. 2020-04, “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (Topic 848), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance is effective for us as of March 12, 2020 through December 31, 2022. We are currently evaluating the impact that this guidance, if elected, will have on our consolidated financial statements. (b) Recently adopted accounting pronouncements ASU No. 2016-02, “Leases” In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset (“ROU”) and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases are classified as either operating or finance under the new guidance. Operating leases result in straight-line expense in the income statement, similar to prior operating lease treatment, and finance leases result in more expense being recognized in the earlier years of the lease term, similar to prior capital lease treatment. For lessors, the update more closely aligns lease accounting to comparable guidance in the new revenue standards described. Effective, July 1, 2019, we adopted the new standard on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In addition, we elected the package of practical expedients permitted under the transition guidance to not reassess (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. In preparation for and upon adoption of this guidance, we have designed and operated internal controls over its implementation, which includes a system solution for lease administration, accounting and disclosures of financial information surrounding our leasing arrangements. The adoption of the guidance on July 1, 2019 resulted in the recognition of ROU assets of $ 77.6 million and lease liabilities of $ 81.3 million, which all related to operating leases. The ROU assets were lower than the lease liabilities due to the derecognition of deferred rent balances of $ 3.7 million. We did not recognize any adjustment to the comparative period presented in the financial statements in accordance with our adoption method. The guidance did not have a material impact on our condensed consolidated statements of income. In our Form 10-K for the year ended June 30, 2019, we estimated that the adoption of the guidance would result in the recognition of additional ROU assets and lease liabilities for operating leases of approximately $ 60.0 million to $ 70.0 million as of July 1, 2019. This range excluded the impact of our evaluation of lease terms, several contracts that may contain an embedded lease and the final assessment of the lease discount rates. During the quarter ended September 30, 2019, we finalized all remaining implementation work and the increase from our estimate of $ 60.0 million to $ 70.0 million to the opening balance of $ 77.6 million was primarily driven by our determination that we were reasonably certain to exercise extension options at some of our major sites, partially offset by our final discount rates generally being lower than the preliminary rate of 3.5 % that was used when calculating our estimated balance upon adoption. See note 9 - Leases for further disclosures related to our leases under the new guidance. (c) Adjustment to prior periods Within our condensed consolidated statements of income for the three and nine months ended March 31, 2020 and 2019, cost of sales has been adjusted to include amortization of acquired intangible assets directly applicable to revenue. As a result, gross profit now includes amortization of acquired intangible assets relating to cost of sales and operating expenses have been reduced by this amount. There was no impact on income from operations, income before taxes or net income, as a result of this reclassification. The adjustments to the previously reported amounts are not material. The table below presents a reconciliation of amortization of acquired intangible assets by income statement caption summing to total amortization of acquired intangible assets as previously reported (in thousands): Three Months Ended Nine Months Ended March 31, 2019 Amortization of intangible assets related to cost of sales $ 10,940 $ 27,095 Amortization of intangible assets related to operating expenses 11,854 24,406 Total $ 22,794 $ 51,501 The table below presents a reconciliation of gross profit as previously reported adjusted for the amortization of acquired intangible assets now included in cost of sales (in thousands): Three Months Ended Nine Months Ended March 31, 2019 Gross profit as previously reported $ 391,910 $ 1,118,734 Amortization of intangible assets related to cost of sales ( 10,940 ) ( 27,095 ) Gross profit $ 380,970 $ 1,091,639

Summary Of Significant Accoun_3

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Summary Of Net Revenue Disaggregated By Product And Region	Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 U.S., Canada and Latin America Devices $ 196,497 $ 181,269 $ 586,907 $ 540,190 Masks and other 197,052 168,726 584,901 494,792 Total Sleep and Respiratory Care $ 393,549 $ 349,995 $ 1,171,808 $ 1,034,982 Software as a Service 89,560 79,942 263,156 190,614 Total $ 483,109 $ 429,937 $ 1,434,964 $ 1,225,596 Combined Europe, Asia and other markets Devices $ 195,038 $ 155,178 $ 509,274 $ 463,053 Masks and other 91,308 77,113 242,431 212,959 Total Sleep and Respiratory Care $ 286,346 $ 232,291 $ 751,705 $ 676,012 Global revenue Devices $ 391,535 $ 336,447 $ 1,096,181 $ 1,003,243 Masks and other 288,360 245,839 827,332 707,751 Total Sleep and Respiratory Care $ 679,895 $ 582,286 $ 1,923,513 $ 1,710,994 Software as a Service 89,560 79,942 263,156 190,614 Total $ 769,455 $ 662,228 $ 2,186,669 $ 1,901,608
Summary Of Contract Balances	March 31, 2020 June 30, 2019 Balance sheet caption Contract assets Accounts receivable, net $ 554,859 $ 528,484 Accounts receivable, net Unbilled revenue, current 8,545 9,834 Prepaid expenses and other current assets Unbilled revenue, non-current 5,920 4,592 Prepaid taxes and other non-current assets Contract liabilities Deferred revenue, current ( 97,110 ) ( 88,667 ) Deferred revenue (current liabilities) Deferred revenue, non-current ( 84,615 ) ( 81,143 ) Deferred revenue (non-current liabilities)
Summary Of Reconciliation Of Amortization Of Acquired Intangible Assets	Three Months Ended Nine Months Ended March 31, 2019 Amortization of intangible assets related to cost of sales $ 10,940 $ 27,095 Amortization of intangible assets related to operating expenses 11,854 24,406 Total $ 22,794 $ 51,501
Summary Of Reconciliation Of Gross Profit	Three Months Ended Nine Months Ended March 31, 2019 Gross profit as previously reported $ 391,910 $ 1,118,734 Amortization of intangible assets related to cost of sales ( 10,940 ) ( 27,095 ) Gross profit $ 380,970 $ 1,091,639

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2020
Segment Information [Abstract]
Summary Of Revenue By Segment And Reconciling Items	Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 Revenue by segment Total Sleep and Respiratory Care $ 679,895 $ 582,286 $ 1,923,513 $ 1,710,994 Software as a Service 89,560 82,196 265,258 194,897 Deferred revenue fair value adjustment - ( 2,254 ) ( 2,102 ) ( 4,283 ) Total Software as a Service 89,560 79,942 263,156 190,614 Total $ 769,455 $ 662,228 $ 2,186,669 $ 1,901,608 Net operating profit by segment Sleep and Respiratory Care $ 250,209 $ 190,203 $ 678,468 $ 562,490 Software as a Service 18,738 20,457 63,874 52,737 Total $ 268,947 $ 210,660 $ 742,342 $ 615,227 Reconciling items Corporate costs $ 31,039 $ 28,635 $ 94,933 $ 95,133 Amortization of acquired intangible assets 20,408 22,794 59,495 51,501 Litigation settlement expenses - - ( 600 ) - Acquisition related expenses - - - 6,123 Deferred revenue fair value adjustment - 2,254 2,102 4,283 Interest income ( 116 ) ( 415 ) ( 766 ) ( 2,014 ) Interest expense 9,968 12,413 31,180 23,608 Loss attributable to equity method investments 5,295 5,996 19,082 9,371 Other, net 10,698 1,054 15,922 4,140 Income before income taxes $ 191,655 $ 137,929 $ 520,994 $ 423,082

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Mar. 31, 2020
Supplemental Balance Sheet Information [Abstract]
Schedule Of Inventories	Inventories March 31, 2020 June 30, 2019 Raw materials $ 98,885 $ 80,861 Work in progress 2,433 2,256 Finished goods 257,454 266,524 Total inventories $ 358,772 $ 349,641
Components Of Property, Plant And Equipment	Property, Plant and Equipment March 31, 2020 June 30, 2019 Property, plant and equipment, at cost $ 903,299 $ 898,975 Accumulated depreciation and amortization ( 506,090 ) ( 511,515 ) Property, plant and equipment, net $ 397,209 $ 387,460
Schedule Of Other Intangible Assets	Other Intangible Assets March 31, 2020 June 30, 2019 Developed/core product technology $ 380,817 $ 401,842 Accumulated amortization ( 183,720 ) ( 157,651 ) Developed/core product technology, net 197,097 244,191 Customer relationships 277,997 273,114 Accumulated amortization ( 73,681 ) ( 68,630 ) Customer relationships, net 204,316 204,484 Other intangibles 163,761 176,351 Accumulated amortization ( 100,211 ) ( 103,076 ) Other intangibles, net 63,550 73,275 Total other intangibles, net $ 464,963 $ 521,950

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Mar. 31, 2020
Goodwill [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill	Nine Months Ended March 31, 2020 Sleep and Respiratory Care SaaS Total Balance at the beginning of the period $ 616,965 $ 1,239,484 $ 1,856,449 Business acquisitions 266 20,284 20,550 Adjustment to fair values of preliminary purchase price allocations 526 16,282 16,808 Foreign currency translation adjustments ( 9,349 ) - ( 9,349 ) Balance at the end of the period $ 608,408 $ 1,276,050 $ 1,884,458

Investments (Tables)

Investments (Tables)	9 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Schedule Of Investments	Nine Months Ended March 31, 2020 2019 Equity method investments Balance at the beginning of the period $ 21,667 $ - Investments 17,500 25,000 Loss attributable to equity method investments ( 19,082 ) ( 9,371 ) Carrying value of equity method investments 20,085 15,629 Non-marketable securities Balance at the beginning of the period $ 30,436 $ 41,226 Investments 14,116 6,092 Impairment of investments ( 14,519 ) ( 8,801 ) Acquisition of controlling interest in previously held investment (note 21) - ( 5,000 ) Carrying value of non-marketable securities 30,033 33,517 Total investments in unconsolidated entities $ 50,118 $ 49,146

Product Warranties (Tables)

Product Warranties (Tables)	9 Months Ended
	Mar. 31, 2020
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs	Nine Months Ended March 31, 2020 2019 Balance at the beginning of the period $ 19,625 $ 19,227 Warranty accruals for the period 10,879 11,601 Warranty costs incurred for the period ( 9,620 ) ( 10,790 ) Foreign currency translation adjustments ( 1,650 ) ( 405 ) Balance at the end of the period $ 19,234 $ 19,633

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2020
Debt [Abstract]
Schedule Of Debt	March 31, 2020 June 30, 2019 Short-term debt $ 12,000 $ 12,012 Deferred borrowing costs ( 13 ) ( 20 ) Short-term debt, net 11,987 11,992 - Long-term debt $ 1,369,000 $ 1,262,000 Deferred borrowing costs ( 4,151 ) ( 3,139 ) Long-term debt, net $ 1,364,849 $ 1,258,861 Total debt $ 1,376,836 $ 1,270,853

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule Of Operating Lease Disclosure	March 31, 2020 Operating lease ROU assets $ 126,277 Operating lease liabilities, current portion 22,795 Operating lease liabilities, non-current portion 107,251 Total operating lease liabilities $ 130,046 Weighted-average remaining lease term (years) 9.0 Weighted-average discount rate 3.07 %
Schedule Of Minimum Lease Payments For Finance, Operating, And Sublease Income Leases	In $000’s Total 2020 2021 2022 2023 2024 2025 Thereafter Minimum lease payments $ 150,844 $ 7,098 $ 24,744 $ 18,349 $ 14,921 $ 12,178 $ 10,560 $ 62,994 Less: imputed interest ( 20,798 ) Total lease liabilities $ 130,046
Schedule Of Future Minimum Lease Payments	Fiscal Years Ending June 30 In $000’s Total 2020 2021 2022 2023 2024 Thereafter Operating leases $ 98,013 $ 23,500 $ 17,161 $ 12,403 $ 9,478 $ 7,916 $ 27,555
Schedule Of Supplemental Cash Flow Information For Operating Leases	Three Months Ended Nine Months Ended March 31, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 6,301 $ 17,352 Right of use assets obtained in exchange for new lease liabilities: Operating leases $ 34,876 $ 51,573

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2020
Stockholders' Equity [Abstract]
Schedule Of Option Activity	Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period 1,260,114 $ 72.91 4.4 Granted 162,180 146.34 Exercised ( 260,666 ) 53.41 Forfeited ( 4,342 ) 110.19 Outstanding at end of period 1,157,286 $ 87.45 4.6 Exercise price of granted options $ 146.34 Options exercisable at end of period 724,040 $ 70.70
Schedule Of Activity Of Restricted Stock Units	Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period 1,446,170 $ 77.21 1.6 Granted 361,986 140.98 Vested* ( 915,450 ) 61.00 Performance factor adjustment 289,678 - Expired / cancelled ( 31,545 ) 89.37 Forfeited ( 5,023 ) 89.37 Outstanding at end of period 1,145,816 $ 103.46 1.8

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share	Three Months Ended March 31, Nine Months Ended March 31, 2020 2019 2020 2019 Numerator: Net income $ 163,137 $ 105,416 $ 443,839 $ 335,791 Denominator: Basic weighted-average common shares outstanding 144,638 143,316 144,112 142,907 Effect of dilutive securities: Stock options and restricted stock units 1,042 1,017 1,378 1,437 Diluted weighted average shares 145,680 144,333 145,490 144,344 Basic earnings per share $ 1.13 $ 0.74 $ 3.08 $ 2.35 Diluted earnings per share $ 1.12 $ 0.73 $ 3.05 $ 2.33

Legal Actions And Contingenci_2

Legal Actions And Contingencies (Tables)	9 Months Ended
	Mar. 31, 2020
Legal Actions And Contingencies [Abstract]
Summary Of Receivables Sold With Recourse	Nine Months Ended March 31, 2020 2019 Total receivables sold: Full recourse $ - $ 28,846 Limited recourse 99,785 70,847 Total $ 99,785 $ 99,693
Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision	March 31, 2020 June 30, 2019 Maximum exposure on outstanding receivables: Full recourse $ 1,870 $ 19,209 Limited recourse 23,436 10,241 Total $ 25,306 $ 29,450 Contingent provision for receivables with recourse $ ( 4,764 ) $ ( 1,752 )

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Mar. 31, 2020
MatrixCare [Member]
Fair Values Of Assets Acquired, Liabilities Assumed, And Estimated Useful Lives	Preliminary as of June 30, 2019 Adjustments Final Intangible assets - useful life Current assets $ 50,325 $ - $ 50,325 Property, plant and equipment 4,401 - 4,401 Trade names 18,000 - 18,000 7 years Developed technology 133,000 - 133,000 7 years Customer relationships 114,000 2,000 116,000 15 years Goodwill 517,995 5,664 523,659 Assets acquired $ 837,721 $ 7,664 $ 845,385 Current liabilities ( 13,751 ) ( 255 ) ( 14,006 ) Deferred revenue ( 18,339 ) ( 166 ) ( 18,505 ) Deferred tax liabilities ( 41,570 ) ( 7,243 ) ( 48,813 ) Debt assumed ( 151,665 ) - ( 151,665 ) Total liabilities assumed $ ( 225,325 ) $ ( 7,664 ) $ ( 232,989 ) Net assets acquired $ 612,396 $ - $ 612,396
Summary Of Reconciliation Of Base Consideration	Base consideration $ 750,000 Cash acquired 15,873 Debt assumed ( 151,665 ) Net working capital and other adjustments ( 1,812 ) Net consideration $ 612,396
Other Acquisitions [Member]
Fair Values Of Assets Acquired, Liabilities Assumed, And Estimated Useful Lives	Final Intangible assets - useful life Current assets $ 31,648 Property, plant and equipment 2,290 Deferred tax assets 5,211 Trade names 7,828 10 years Non-compete 1,000 3 years Developed technology 48,280 5 to 6 years Customer relationships 53,712 5 to 15 years Goodwill 287,469 Assets acquired $ 437,438 Current liabilities ( 7,648 ) Deferred revenue ( 3,619 ) Deferred tax liabilities ( 2,367 ) Debt assumed ( 35,104 ) Total liabilities assumed $ ( 48,738 ) Net assets acquired $ 388,700

Summary Of Significant Accoun_4

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	Jul. 01, 2019	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2018
Summary Of Significant Accounting Policies [Line Items]
ROU assets		$ 126,277
Lease liabilities		$ 130,046
Cumulative effect of change in accounting standards				$ (188,799)
Estimated discount rate			3.50%
ASU 2016-02 [Member]
Summary Of Significant Accounting Policies [Line Items]
ROU assets	$ 77,600
Lease liabilities	81,300
Derecognized deferred rent	3,700
Cumulative effect of change in accounting standards	77,600
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue recognized over a period of		1 year
Additional ROU assets and lease liabilities due to guidance	60,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue recognized over a period of		5 years
Additional ROU assets and lease liabilities due to guidance	$ 70,000

Summary Of Significant Accoun_5

Summary Of Significant Accounting Policies (Summary Of Net Revenue Disaggregated By Product And Region) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
U.S., Canada And Latin America [Member]
Disaggregation of Revenue [Line Items]
Net revenue	$ 483,109	$ 429,937	$ 1,434,964	$ 1,225,596
U.S., Canada And Latin America [Member] | Devices [Member]
Disaggregation of Revenue [Line Items]
Net revenue	196,497	181,269	586,907	540,190
U.S., Canada And Latin America [Member] | Masks And Other [Member]
Disaggregation of Revenue [Line Items]
Net revenue	197,052	168,726	584,901	494,792
U.S., Canada And Latin America [Member] | Total Sleep And Respiratory Care [Member]
Disaggregation of Revenue [Line Items]
Net revenue	393,549	349,995	1,171,808	1,034,982
U.S., Canada And Latin America [Member] | Software As A Service [Member]
Disaggregation of Revenue [Line Items]
Net revenue	89,560	79,942	263,156	190,614
Combined Europe, Asia And Other Markets [Member] | Devices [Member]
Disaggregation of Revenue [Line Items]
Net revenue	195,038	155,178	509,274	463,053
Combined Europe, Asia And Other Markets [Member] | Masks And Other [Member]
Disaggregation of Revenue [Line Items]
Net revenue	91,308	77,113	242,431	212,959
Combined Europe, Asia And Other Markets [Member] | Total Sleep And Respiratory Care [Member]
Disaggregation of Revenue [Line Items]
Net revenue	286,346	232,291	751,705	676,012
Global [Member]
Disaggregation of Revenue [Line Items]
Net revenue	769,455	662,228	2,186,669	1,901,608
Global [Member] | Devices [Member]
Disaggregation of Revenue [Line Items]
Net revenue	391,535	336,447	1,096,181	1,003,243
Global [Member] | Masks And Other [Member]
Disaggregation of Revenue [Line Items]
Net revenue	288,360	245,839	827,332	707,751
Global [Member] | Total Sleep And Respiratory Care [Member]
Disaggregation of Revenue [Line Items]
Net revenue	679,895	582,286	1,923,513	1,710,994
Global [Member] | Software As A Service [Member]
Disaggregation of Revenue [Line Items]
Net revenue	$ 89,560	$ 79,942	$ 263,156	$ 190,614

Summary Of Significant Accoun_6

Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Contract assets
Accounts receivable, net	$ 554,859	$ 528,484
Contract liabilities
Deferred revenue, current	(97,110)	(88,667)
Deferred revenue, non-current	(84,615)	(81,143)
Accounts Receivable, Net [Member]
Contract assets
Accounts receivable, net	554,859	528,484
Prepaid Expenses And Other Current Assets [Member]
Contract assets
Unbilled revenue, current	8,545	9,834
Prepaid Taxes And Other Non Current Assets [Member]
Contract assets
Unbilled revenue, non-current	5,920	4,592
Deferred Revenue Current Liabilities [Member]
Contract liabilities
Deferred revenue, current	(97,110)	(88,667)
Deferred Revenue Non-Current Liabilities [Member]
Contract liabilities
Deferred revenue, non-current	$ (84,615)	$ (81,143)

Summary Of Significant Accoun_7

Summary Of Significant Accounting Policies (Summary Of Reconciliation Of Amortization Of Acquired Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Amortization of intangible assets	$ 12,136	$ 10,940	$ 37,623	$ 27,095
Previously Reported [Member]
Amortization of intangible assets		22,794		51,501
Restatement Adjustment [Member]
Amortization of intangible assets		$ 11,854		$ 24,406

Summary Of Significant Accoun_8

Summary Of Significant Accounting Policies (Summary Of Reconciliation Of Gross Profit) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Amortization of intangible assets related to cost of sales	$ (12,136)	$ (10,940)	$ (37,623)	$ (27,095)
Gross profit	$ 449,662	380,970	$ 1,268,413	1,091,639
Previously Reported [Member]
Amortization of intangible assets related to cost of sales		(22,794)		(51,501)
Gross profit		$ 391,910		$ 1,118,734

Segment Information (Summary Of

Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 769,455,000	$ 662,228,000	$ 2,186,669,000	$ 1,901,608,000
Operating Income (Loss)	217,500,000	156,977,000	586,412,000	458,187,000
Amortization of acquired intangible assets	8,272,000	11,854,000	21,872,000	24,406,000
Litigation settlement expenses			(600,000)
Acquisition related expenses			0	6,123,000
Interest income	(116,000)	(415,000)	(766,000)	(2,014,000)
Interest expense	9,968,000	12,413,000	31,180,000	23,608,000
Loss attributable to equity method investments	(5,295,000)	(5,996,000)	(19,082,000)	(9,371,000)
Other, net	(10,698,000)	(1,054,000)	(15,922,000)	(4,140,000)
Income before income taxes	191,655,000	137,929,000	520,994,000	423,082,000
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)	268,947,000	210,660,000	742,342,000	615,227,000
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Deferred revenue fair value adjustment		(2,254,000)	(2,102,000)	(4,283,000)
Corporate costs	31,039,000	28,635,000	94,933,000	95,133,000
Amortization of acquired intangible assets	20,408,000	22,794,000	59,495,000	51,501,000
Deferred revenue fair value adjustment		2,254,000	2,102,000	4,283,000
Interest income	(116,000)	(415,000)	(766,000)	(2,014,000)
Interest expense	9,968,000	12,413,000	31,180,000	23,608,000
Loss attributable to equity method investments	5,295,000	5,996,000	19,082,000	9,371,000
Other, net	10,698,000	1,054,000	15,922,000	4,140,000
Income before income taxes	191,655,000	137,929,000	520,994,000	423,082,000
Total Sleep And Respiratory Care [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	679,895,000	582,286,000	1,923,513,000	1,710,994,000
Operating Income (Loss)	250,209,000	190,203,000	678,468,000	562,490,000
Software As A Service Before Deferred Revenue Adjustment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	89,560,000	82,196,000	265,258,000	194,897,000
Software As A Service [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Deferred revenue fair value adjustment		(2,254,000)	(2,102,000)	(4,283,000)
Revenues	89,560,000	79,942,000	263,156,000	190,614,000
Operating Income (Loss)	$ 18,738,000	20,457,000	63,874,000	52,737,000
Deferred revenue fair value adjustment		$ 2,254,000	$ 2,102,000	$ 4,283,000

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Supplemental Balance Sheet Information [Abstract]
Raw materials	$ 98,885	$ 80,861
Work in progress	2,433	2,256
Finished goods	257,454	266,524
Total inventories	$ 358,772	$ 349,641

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Supplemental Balance Sheet Information [Abstract]
Property, plant and equipment, gross	$ 903,299	$ 898,975
Accumulated depreciation and amortization	(506,090)	(511,515)
Property, plant and equipment, net	$ 397,209	$ 387,460

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information (Schedule Of Other Intangible Assets, Net) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Jun. 30, 2019
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 464,963	$ 521,950
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	380,817	401,842
Accumulated amortization	(183,720)	(157,651)
Total other intangibles, net	197,097	244,191
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	277,997	273,114
Accumulated amortization	(73,681)	(68,630)
Total other intangibles, net	204,316	204,484
Other Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	163,761	176,351
Accumulated amortization	(100,211)	(103,076)
Total other intangibles, net	$ 63,550	$ 73,275
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	15 years

Goodwill (Schedule Of Changes I

Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2020USD ($)
Balance at the beginning of the period	$ 1,856,449
Business acquisitions	20,550
Adjustment to fair values of preliminary purchase price allocations	16,808
Foreign currency translation adjustments	(9,349)
Balance at the end of the period	1,884,458
Sleep And Respiratory [Member]
Balance at the beginning of the period	616,965
Business acquisitions	266
Adjustment to fair values of preliminary purchase price allocations	526
Foreign currency translation adjustments	(9,349)
Balance at the end of the period	608,408
Saas [Member]
Balance at the beginning of the period	1,239,484
Business acquisitions	20,284
Adjustment to fair values of preliminary purchase price allocations	16,282
Foreign currency translation adjustments
Balance at the end of the period	$ 1,276,050

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Investments [Abstract]
Aggregate carrying amount of equity investments	$ 50,118	$ 49,146
Impairment losses related to equity investments	$ 14,519	$ 8,801

Investments (Schedule Of Invest

Investments (Schedule Of Investments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Investments			$ 31,616	$ 31,092
Impairment of investments			(14,519)	(8,801)
Loss attributable to equity method investments	$ (5,295)	$ (5,996)	(19,082)	(9,371)
Acquisition of controlling interest in previously held investment (note 21)				(5,000)
Carrying value of investments	50,118	49,146	50,118	49,146
Equity Method Investments [Member]
Balance at the beginning of the period			21,667
Investments			17,500	25,000
Loss attributable to equity method investments			(19,082)	(9,371)
Carrying value of investments	20,085	15,629	20,085	15,629
Non-marketable Securities [Member]
Balance at the beginning of the period			30,436	41,226
Investments			14,116	6,092
Impairment of investments			(14,519)	(8,801)
Carrying value of investments	$ 30,033	$ 33,517	$ 30,033	$ 33,517

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended
	Jun. 30, 2018	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019
Income Taxes [Line Items]
Income taxes payable				$ 68,278		$ 68,278		$ 73,248
Income taxes paid						150,801	$ 211,816
Income tax expense (benefit)				$ 28,518	$ 32,513	$ 77,155	$ 87,291
Australian Taxation Office [Member]
Income Taxes [Line Items]
Tax liabilities related to assessments	$ 75,900	$ 75,900	$ 151,700
Interest related to assessments			$ 38,400
Percentage of penalties on additional income tax	50.00%
Income taxes paid		$ 75,900
Australian Taxation Office [Member] | Tax Year 2014 To 2018 [Member]
Income Taxes [Line Items]
Tax year under audit						2018
Australian Taxation Office [Member] | Minimum [Member] | Tax Year 2009 To 2013 [Member]
Income Taxes [Line Items]
Tax year under audit			2009			2009
Australian Taxation Office [Member] | Minimum [Member] | Tax Year 2014 To 2018 [Member]
Income Taxes [Line Items]
Tax year under audit						2014
Australian Taxation Office [Member] | Maximum [Member] | Tax Year 2009 To 2013 [Member]
Income Taxes [Line Items]
Tax year under audit			2013			2013
Australian Taxation Office [Member] | Maximum [Member] | Tax Year 2014 To 2018 [Member]
Income Taxes [Line Items]
Tax year under audit						2018

Product Warranties (Schedule Of

Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Product Warranties [Abstract]
Balance at the beginning of the period	$ 19,625	$ 19,227
Warranty accruals for the period	10,879	11,601
Warranty costs incurred for the period	(9,620)	(10,790)
Foreign currency translation adjustments	(1,650)	(405)
Balance at the end of the period	$ 19,234	$ 19,633

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	Nov. 05, 2018	Apr. 17, 2018	Mar. 31, 2020	Jun. 30, 2019
Debt Instrument [Line Items]
Debt to consolidated EBITDA ratio			3.50
Outstanding under the revolving credit facility and term credit facility			$ 1,376,836,000	$ 1,270,853,000
Senior notes, carrying amount			500,000,000
Revolving Credit Facility And Term Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term debt, fair value			881,000,000	$ 1,274,000,000
MUFG Union Bank [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,600,000,000	$ 800,000,000
Uncommitted option to increase credit facility	$ 300,000,000	300,000,000
MUFG Union Bank [Member] | ResMed Limited [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		200,000,000
MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 800,000,000
Available for draw			$ 895,000,000
MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | Revolving Credit Facility And Term Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility termination date			Apr. 17, 2023
Interest rate on outstanding principal amount			1.90%
MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | ResMed Limited [Member] | Term Credit Agreement [Member]
Debt Instrument [Line Items]
Principal payment			$ 6,000,000
Minimum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility			0.10%
Minimum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | ResMed Limited [Member] | Term Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus			0.75%
Minimum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | ResMed Limited [Member] | Term Credit Agreement [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus			0.00%
Maximum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility			0.175%
Maximum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | ResMed Limited [Member] | Term Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus			1.50%
Maximum [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | ResMed Limited [Member] | Term Credit Agreement [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus			0.50%
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, fair value			$ 521,100,000
3.24% Senior Notes Due July 10, 2026 [Member]
Debt Instrument [Line Items]
Principal amount			$ 250,000,000
Interest rate			3.24%
Maturity date			Jul. 10, 2026
3.45% Senior Notes Due July 10, 2029 [Member]
Debt Instrument [Line Items]
Principal amount			$ 250,000,000
Interest rate			3.45%
Maturity date			Jul. 10, 2029

Debt (Schedule Of Debt) (Detail

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Debt [Abstract]
Short-term debt	$ 12,000	$ 12,012
Deferred borrowing costs	(13)	(20)
Short-term debt, net	11,987	11,992
Long-term debt	1,369,000	1,262,000
Deferred borrowing costs	(4,151)	(3,139)
Long-term debt, net	1,364,849	1,258,861
Total debt	$ 1,376,836	$ 1,270,853

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Operating lease costs	$ 7.2	$ 19.6	$ 23.4	$ 21.1	$ 20.1
Operating lease commitments not yet commenced	$ 14	$ 14
Maximum [Member]
Remaining lease terms	15 years	15 years
Lease terms, not yet commenced	11 years	11 years
Minimum [Member]
Remaining lease terms	1 year	1 year
Lease terms, not yet commenced	8 years	8 years

Leases (Schedule Of Operating L

Leases (Schedule Of Operating Lease Assets And Liabilities) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease ROU assets	$ 126,277
Operating lease liabilities, current portion	22,795
Operating lease liabilities, non-current portion	107,251
Total operating lease liabilities	$ 130,046
Weighted-average remaining lease term (years)	9 years
Weighted-average discount rate	3.07%

Leases (Schedule Of Minimum Lea

Leases (Schedule Of Minimum Lease Payments For Finance, Operating, And Sublease Income Leases) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Leases [Abstract]
2020	$ 7,098
2021	24,744
2022	18,349
2023	14,921
2024	12,178
2025	10,560
Thereafter	62,994
Total lease payments	150,844
Less: imputed interest	(20,798)
Total operating lease liabilities	$ 130,046

Leases (Schedule Of Future Mini

Leases (Schedule Of Future Minimum Lease Payments) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Commitments [Abstract]
2020	$ 23,500
2021	17,161
2022	12,403
2023	9,478
2024	7,916
Thereafter	27,555
Total minimum lease payments	$ 98,013

Leases (Schedule Of Supplementa

Leases (Schedule Of Supplemental Cash Flow Information For Operating Leases) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows from operating leases	$ 6,301	$ 17,352
Right of use assets obtained in exchange for new lease liabilities, Operating leases	$ 34,876	$ 51,573

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Apr. 30, 1997
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares repurchased under repurchase program		41,800,000	200,000
Cost of common shares repurchased	$ 22,845	$ 1,600,000	$ 22,800
Total number of shares repurchased pursuant to the repurchase program		41,836,234		41,836,234
Total cost of shares repurchased pursuant to the repurchase program		$ 1,623,256		$ 1,623,256
Additional shares that can be repurchased under the approved share repurchase program		12,900,000
Preferred stock, shares authorized		2,000,000		2,000,000
Preferred stock at par value		$ 0.01		$ 0.01
Preferred stock, shares issued		0		0
Shares issued under Employee Stock Purchase Plan		137,000	129,000
Treasury Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares repurchased under repurchase program	200,000
Cost of common shares repurchased	$ 22,844
Series A Junior Participating Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized					2,000,000
Preferred stock at par value					$ 0.01
Preferred stock, shares issued		0		0
Preferred stock, shares outstanding		0		0
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		7 years
Common stock authorized for issuance		51,100,000
Number of securities remaining available for future issuance		15,800,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance		2,100,000
Minimum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Maximum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Option Activity) (Details)	9 Months Ended	12 Months Ended
	Mar. 31, 2020$ / sharesshares	Jun. 30, 2019$ / sharesshares
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period | shares	1,260,114
Options, Granted | shares	162,180
Options, Exercised | shares	(260,666)
Options, Forfeited | shares	(4,342)
Options, Outstanding at end of period | shares	1,157,286	1,260,114
Options, Exercise price of granted options	$ 146.34
Options exercisable at end of period | shares	724,040
Weighted Average Exercise Price, Outstanding at beginning of period	$ 72.91
Weighted Average Exercise Price, Granted	146.34
Weighted Average Exercise Price, Exercised	53.41
Weighted Average Exercise Price, Forfeited	110.19
Weighted Average Exercise Price, Outstanding at end of period	87.45	$ 72.91
Weighted Average Exercise Price, Options exercisable at end of period	$ 70.70
Weighted Average Remaining Contractual Term in Years, Outstanding	4 years 7 months 6 days	4 years 4 months 24 days

Stockholders' Equity (Schedul_2

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	1,446,170
Restricted Stock Units, Granted	361,986
Restricted Stock Units, Vested	(915,450)
Restricted Stock Units, Performance factor adjustment	289,678
Restricted Stock Units, Expired / cancelled	(31,545)
Restricted Stock Units, Forfeited	(5,023)
Restricted Stock Units, Outstanding at end of period	1,145,816	1,446,170
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 77.21
Weighted Average Grant-Date Fair Value, Granted	140.98
Weighted Average Grant-Date Fair Value, Vested	61
Weighted Average Grant-Date Fair Value, Expired / cancelled	89.37
Weighted Average Grant-Date Fair Value, Forfeited	89.37
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 103.46	$ 77.21
Weighted Average Remaining Contractual Term in Years, Outstanding	1 year 9 months 18 days	1 year 7 months 6 days
Exercisable shares, netted for tax	305,719

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Stock options and restricted stock units not included in the computation of diluted earnings per share	267,556,000	356,583,000	128,789	161,314

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net income	$ 163,137	$ 160,554	$ 120,148	$ 105,416	$ 124,639	$ 105,738	$ 443,839	$ 335,791
Denominator:
Basic weighted-average common shares outstanding	144,638			143,316			144,112	142,907
Effect of dilutive securities:
Stock options and restricted stock units	1,042			1,017			1,378	1,437
Diluted weighted average shares	145,680			144,333			145,490	144,344
Basic earnings per share	$ 1.13			$ 0.74			$ 3.08	$ 2.35
Diluted earnings per share	$ 1.12			$ 0.73			$ 3.05	$ 2.33

Legal Actions And Contingenci_3

Legal Actions And Contingencies (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended			9 Months Ended
	Jun. 30, 2018	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2020	Jun. 30, 2019
Loss Contingencies [Line Items]
Income taxes payable				$ 68,278	$ 73,248
Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Percentage of penalties on additional income tax	50.00%
Tax liabilities related to assessments	$ 75,900	$ 75,900	$ 151,700
Interest related to assessments			$ 38,400
Tax Year 2009 To 2013 [Member] | Minimum [Member] | Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Tax year under audit			2009	2009
Tax Year 2009 To 2013 [Member] | Maximum [Member] | Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Tax year under audit			2013	2013
Tax Year 2014 To 2018 [Member] | Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Tax year under audit				2018
Tax Year 2014 To 2018 [Member] | Minimum [Member] | Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Tax year under audit				2014
Tax Year 2014 To 2018 [Member] | Maximum [Member] | Australian Taxation Office [Member]
Loss Contingencies [Line Items]
Tax year under audit				2018

Legal Actions And Contingenci_4

Legal Actions And Contingencies (Summary Of Receivables Sold With Recourse) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold	$ 99,785	$ 99,693
Full Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold		28,846
Limited Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold	$ 99,785	$ 70,847

Legal Actions And Contingenci_5

Legal Actions And Contingencies (Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jun. 30, 2019
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	$ 25,306	$ 29,450
Contingent provision for receivables with recourse	(4,764)	(1,752)
Full Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	1,870	19,209
Limited Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	$ 23,436	$ 10,241

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) - USD ($)	Jan. 06, 2019	Nov. 13, 2018	Jul. 06, 2018	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Jan. 31, 2020	Oct. 15, 2018
Business Combinations [Line Items]
Income (loss) from operations				$ 191,655,000	$ 137,929,000	$ 520,994,000	$ 423,082,000
Amortization of intangible assets				$ 12,136,000	$ 10,940,000	37,623,000	27,095,000
Acquisition related expenses						$ 0	$ 6,123,000
SnapWorx, LLC [Member]
Business Combinations [Line Items]
Percentage of acquisition shares									100.00%
MatrixCare [Member]
Business Combinations [Line Items]
Percentage of acquisition shares		100.00%
Total purchase price of acquisition		$ 750,000,000
Healthcarefirst [Member]
Business Combinations [Line Items]
Percentage of acquisition shares			100.00%
Total purchase price of acquisition			$ 126,300,000
HB Healthcare [Member]
Business Combinations [Line Items]
Percentage of acquisition shares										100.00%
Propeller Health [Member]
Business Combinations [Line Items]
Total purchase price of acquisition	$ 242,900,000
Income (loss) from operations								$ 1,900,000

Business Combinations (Fair Val

Business Combinations (Fair Values Of Assets Acquired, Liabilities Assumed, And Estimated Useful Lives) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Jun. 30, 2019
Business Combinations [Line Items]
Goodwill	$ 1,884,458	$ 1,856,449
MatrixCare [Member]
Business Combinations [Line Items]
Current assets	50,325
Property, plant and equipment	4,401
Goodwill	523,659
Assets acquired	845,385
Current liabilities	(14,006)
Deferred revenue	(18,505)
Deferred tax liabilities	(48,813)
Debt assumed	(151,665)
Total liabilities assumed	(232,989)
Net assets acquired	612,396
MatrixCare [Member] | Previously Reported [Member]
Business Combinations [Line Items]
Current assets		50,325
Property, plant and equipment		4,401
Goodwill		517,995
Assets acquired		837,721
Current liabilities		(13,751)
Deferred revenue		(18,339)
Deferred tax liabilities		(41,570)
Debt assumed		(151,665)
Total liabilities assumed		(225,325)
Net assets acquired		612,396
MatrixCare [Member] | Adjustments [Member]
Business Combinations [Line Items]
Goodwill		5,664
Assets acquired		7,664
Current liabilities		(255)
Deferred revenue		(166)
Deferred tax liabilities		(7,243)
Total liabilities assumed		(7,664)
Other Acquisitions [Member]
Business Combinations [Line Items]
Current assets	31,648
Property, plant and equipment	2,290
Deferred tax assets	5,211
Goodwill	287,469
Assets acquired	437,438
Current liabilities	(7,648)
Deferred revenue	(3,619)
Deferred tax liabilities	(2,367)
Debt assumed	(35,104)
Total liabilities assumed	(48,738)
Net assets acquired	388,700
Trade Names [Member] | MatrixCare [Member]
Business Combinations [Line Items]
Intangible assets	$ 18,000
Intangible assets, useful life	7 years
Trade Names [Member] | MatrixCare [Member] | Previously Reported [Member]
Business Combinations [Line Items]
Intangible assets		18,000
Trade Names [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets	$ 7,828
Intangible assets, useful life	10 years
Non-Compete [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets	$ 1,000
Intangible assets, useful life	3 years
Developed Technology [Member] | MatrixCare [Member]
Business Combinations [Line Items]
Intangible assets	$ 133,000
Intangible assets, useful life	7 years
Developed Technology [Member] | MatrixCare [Member] | Previously Reported [Member]
Business Combinations [Line Items]
Intangible assets		133,000
Developed Technology [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets	$ 48,280
Developed Technology [Member] | Minimum [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets, useful life	5 years
Developed Technology [Member] | Maximum [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets, useful life	6 years
Customer Relationships [Member] | MatrixCare [Member]
Business Combinations [Line Items]
Intangible assets	$ 116,000
Intangible assets, useful life	15 years
Customer Relationships [Member] | MatrixCare [Member] | Previously Reported [Member]
Business Combinations [Line Items]
Intangible assets		114,000
Customer Relationships [Member] | MatrixCare [Member] | Adjustments [Member]
Business Combinations [Line Items]
Intangible assets		$ 2,000
Customer Relationships [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets	$ 53,712
Intangible assets, useful life	5 years
Customer Relationships [Member] | Maximum [Member] | Other Acquisitions [Member]
Business Combinations [Line Items]
Intangible assets, useful life	15 years

Business Combinations (Summary

Business Combinations (Summary Of Reconciliation Of Base Consideration) (Details) - MatrixCare [Member] $ in Thousands	Nov. 13, 2018USD ($)
Business Acquisition [Line Items]
Base consideration	$ 750,000
Cash acquired	15,873
Debt assumed	(151,665)
Net working capital and other adjustments	(1,812)
Net consideration	$ 612,396